Quanterix's Lucent Diagnostics: LucentAD Complete

Quanterix brand Lucent Diagnostics has launched its LucentAD Complete multi-marker blood test for diagnosing Alzheimer's disease. The test uses the measurement of five markers (p-tau 217, Aβ42/40, NfL, and GFAP) combined with a proprietary algorithm to differentiate between patients with and without the amyloid brain pathology characteristic of Alzheimer's. According to the company, the test decreases the number of patients with indeterminate test results compared to testing with single markers like p-tau 217.